These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22381412)

  • 1. Deep vein thrombosis and pulmonary embolism in patients undergoing total hip arthroplasty: the promise of new oral anticoagulants.
    Muntz J
    J Surg Orthop Adv; 2011; 20(4):215-9. PubMed ID: 22381412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty.
    Friedman RJ
    Orthopedics; 2009 Dec; 32(12 Suppl):79-84. PubMed ID: 20201481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of apixaban for venous and arterial thromboembolic disease.
    Prom R; Spinler SA
    Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DVT prophylaxis: better living through chemistry: affirms.
    Pellegrini VD
    Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with thromboprophylaxis for orthopedic patients and their impact on outcome.
    Muntz JE; O'Connor PJ; Yin H; Vogenberg FR
    Am J Orthop (Belle Mead NJ); 2007 Apr; 36(4):193-7. PubMed ID: 17515185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
    Zufferey PJ; Samama CM; Rosencher N
    Thromb Haemost; 2010 Dec; 104(6):1083-4. PubMed ID: 20886198
    [No Abstract]   [Full Text] [Related]  

  • 10. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty.
    Colwell CW
    Orthopedics; 2009 Dec; 32(12 Suppl):67-73. PubMed ID: 20201479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis and peripheral nerve blocks in patients undergoing joint arthroplasty.
    Chelly JE; Schilling D
    J Arthroplasty; 2008 Apr; 23(3):350-4. PubMed ID: 18358371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
    Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between deep vein thrombosis and pulmonary embolism following THA and TKA.
    Bosque J; Coleman SI; Di Cesare P
    Orthopedics; 2012 Mar; 35(3):228-33; quiz 234-5. PubMed ID: 22385601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
    Motsch J; Walther A; Bock M; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):52-8. PubMed ID: 16547433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.